- PATIENT PLANS
- ABOUT US
- CONTACT US
Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.
If you missed the webinar, you can still watch the recording here.
Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar.
Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio.
Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT.
Dr. Belisario Arango covered the following topics:
Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients?
Where is the future of cancer care going?
Healthcare reform is undergoing a wave of radical change and disruptive innovation, with stakeholders transitioning to value-based care delivery models to reduce costs and improve quality of care. At the same time, leveraging advanced technologies, experimenting with various business models, and developing new relationships are changing the way that medicine is practiced.
Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together.
We continue to support you and your loved ones by sharing new savings.
The American Turkish Society is pleased to announce the sixth class of "Young Society Leaders," a group of 25 accomplished professionals with a demonstrated record of leadership ability and commitment to serve the U.S.-Turkish community at large.
Since the emergence of new data released in 2017, moderate hypofractionation has proven to be a quicker and efficacious method to administer radiation therapy to patients with prostate cancer.
Testing for genetic alterations has become an important step in the treatment of patients with ovarian cancer. Although much has been achieved, says Mike Janicek, MD, there needs to be more widespread use of genetic testing in order to push the field forward.
For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of anti-angiogenic strategies given with chemotherapy and in the maintenance setting. In the past decade, numerous poly(ADP-ribose) polymerase (PARP)-inhibiting agents have been assessed.
Cancer cells constantly grow and divide, which means that they need a consistent energy supply. A new study looks at how cancer derives fuel from fat cells and finds a potential mechanism to starve the tumor of its nutrition.
Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.
The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).
Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.
Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.
Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day.